Ivabradina Cinfa

Ivabradine, the active ingredient in Ivabradina Cinfa, is an If channel inhibitor presented as an oral tablet for oral use. It is employed to lower heart rate in patients with chronic stable angina pectoris and in those with heart failure with reduced ejection fraction.

GNH USA supplies Ivabradina Cinfa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing regulatory documentation for global distribution, including batch release certificates and stability data.

Ivabradine acts on the cardiac sinus node to reduce heart rate, benefiting conditions where heart‑rate control improves outcomes. - Chronic stable angina pectoris: reduces myocardial oxygen demand by lowering heart rate, relieving anginal symptoms. - Heart failure with reduced ejection fraction: improves left‑ventricular function and lowers hospitalization risk by controlling heart rate. - Exercise‑induced angina: facilitates better exercise tolerance by preventing excessive heart‑rate rise.

Common Side Effects: - Bradycardia: slowed heart rate that may cause fatigue. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache: mild to moderate pain. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Severe bradycardia: symptomatic heart‑rate <50 bpm requiring medical attention. - Atrial fibrillation: irregular rhythm that may need treatment. - Allergic reaction: rash, swelling, or anaphylaxis.

When prescribing Ivabradina Cinfa, clinicians should consider the following precautions: - Heart‑rate monitoring: check resting heart rate before initiation and periodically thereafter. - Contraindication in sick sinus syndrome: avoid use in patients with intrinsic sinus node dysfunction. - Severe hepatic impairment: use with caution or avoid. - Concurrent strong CYP3A4 inhibitors: avoid co‑administration. - Pregnancy and lactation: safety not established; weigh risks and benefits. Store below 25°C: keep in the original pack, protect from moisture.

Ivabradina Cinfa may interact with several drug classes. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase ivabradine exposure. - Other bradycardic agents (e.g., beta‑blockers, digoxin): combined use can cause excessive heart‑rate reduction. - Concomitant use with other If channel inhibitors: avoid. Moderate Interactions (Monitor Closely): - Calcium‑channel blockers (verapamil, diltiazem): may modestly raise ivabradine levels. - CYP3A4 inducers (rifampicin, carbamazepine): may reduce efficacy. - Antihypertensives (ACE inhibitors, ARBs): monitor blood pressure.